Skip Nav Destination
Issues
Neurodegenerative Diseases 2005, Vol. 2, No. 3-4
Special Section
Title Page / Table of Contents
Neurodegener Dis (2006) 2 (3-4): 109–111.
https://doi.org/10.1159/000090899
Paper
Structure of SOD1 Mutants: Implications for ALS
Mutant SOD1 Instability: Implications for Toxicity in Amyotrophic Lateral Sclerosis
Neurodegener Dis (2006) 2 (3-4): 115–127.
https://doi.org/10.1159/000089616
Molecular Signaling in ALS
Inter- and Intracellular Signaling in Amyotrophic Lateral Sclerosis: Role of p38 Mitogen-Activated Protein Kinase
C. Bendotti; M. Bao Cutrona; C. Cheroni; G. Grignaschi; D. Lo Coco; M. Peviani; M. Tortarolo; P. Veglianese; E. Zennaro
Neurodegener Dis (2006) 2 (3-4): 128–134.
https://doi.org/10.1159/000089617
Anti-ALS Activity of Alsin, the Product of the ALS2 Gene, and Activity-Dependent Neurotrophic Factor
Neurodegener Dis (2006) 2 (3-4): 135–138.
https://doi.org/10.1159/000089618
Toxicity Pathways in ALS
Complexity of Astrocyte-Motor Neuron Interactions in Amyotrophic Lateral Sclerosis
Mariana Pehar; Marcelo R. Vargas; Patricia Cassina; Ana G. Barbeito; Joseph S. Beckman; Luis Barbeito
Neurodegener Dis (2006) 2 (3-4): 139–146.
https://doi.org/10.1159/000089619
Excitotoxicity and Amyotrophic Lateral Sclerosis
Neurodegener Dis (2006) 2 (3-4): 147–159.
https://doi.org/10.1159/000089620
Enprofylline Protects Motor Neurons from in vitro Excitotoxic Challenge
Neurodegener Dis (2006) 2 (3-4): 160–165.
https://doi.org/10.1159/000089621
Implications for the Kynurenine Pathway and Quinolinic Acid in Amyotrophic Lateral Sclerosis
Neurodegener Dis (2006) 2 (3-4): 166–176.
https://doi.org/10.1159/000089622
Diagnostic Markers of ALS
Amyotrophic Lateral Sclerosis: New Developments in Diagnostic Markers
Reinhard Dengler; Nils von Neuhoff; Johannes Bufler; Klaus Krampfl; Thomas Peschel; Julian Grosskreutz
Neurodegener Dis (2006) 2 (3-4): 177–184.
https://doi.org/10.1159/000089623
Reticulons as Markers of Neurological Diseases: Focus on Amyotrophic Lateral Sclerosis
Anissa Fergani; Luc Dupuis; Natasa Jokic; Yves Larmet; Marc de Tapia; Frederique Rene; Jean-Philippe Loeffler; Jose-Luis Gonzalez de Aguilar
Neurodegener Dis (2006) 2 (3-4): 185–194.
https://doi.org/10.1159/000089624
Clinical and Epidemiological Aspects of ALS
Lead Exposure as a Risk Factor for Amyotrophic Lateral Sclerosis
Neurodegener Dis (2006) 2 (3-4): 195–201.
https://doi.org/10.1159/000089625
Hypermetabolism in ALS: Correlations with Clinical and Paraclinical Parameters
Neurodegener Dis (2006) 2 (3-4): 202–207.
https://doi.org/10.1159/000089626
Clinical Trials in ALS: What Did We Learn from Recent Trials in Humans?
Neurodegener Dis (2006) 2 (3-4): 208–214.
https://doi.org/10.1159/000089627
Therapeutic Strategies
Preclinical Trials – An Update on Translational Research in ALS
Neurodegener Dis (2006) 2 (3-4): 215–219.
https://doi.org/10.1159/000089628
Promises and Challenges in Developing RNAi as a Research Tool and Therapy for Neurodegenerative Diseases
Neurodegener Dis (2006) 2 (3-4): 220–231.
https://doi.org/10.1159/000089629
